BCAA 8:1:1PRO the most advanced BCAA formula 8:1:1 ratio.

Categories: , .
Vota este post


BCAA 8:1:1PRO from Beverly Nutrition is the most advanced formula 8:1:1 ratio (8 parts of Leucine, 1 of Isoleucine and 1 of Valine), moreover we have added the amino acid L – Glutamine to improve the power of this supplement. This combination is much more superior to the usual amino acid ratio of the market, allowing you to absorb a greater amount of amino acids in less time and your ability to promote recovery after training. BCAA 8:1:1PRO improves your muscle development.

BCAA 8:1:1PRO is essential aminoacids because your body cannot produce them under stress. These amino acids are suitable for muscles to absorb it immediately multiplying their profits and counteracting muscle catabolism.

BCAA 8:1:1PRO stimulates the synthesis of muscle proteins. Moreover the high level of these aminoacids causes an anabolic environment for your muscles which causes them to develop beyond their limits. During an intense workout branched-chain amino acids serve as fuel for your muscles.

Ingredients: L – Leucine (Instant), L – Isoleucine (Instant), L – Valine (Instant) 8:1:1 ratio, L – Glutamine (Instant), Vitamin B6, Maltodextrine, sweetener (Sucralose E955) and flavour.

Bottle with: 300 g

Flavours: Tropical Blue and Watermelon.

Suggested used: Mix 2 scoops (10gr) in 200 – 250 ml of water and take after workout or as recommended by physician


LEGAL NOTE: Products reviewed here are food supplements or as established by European Directive 2002/46/EC on food supplements and all can be legally sold in all countries of the European Community, under Articles 28, 29 and 30 of the treaty the European Community and by Articles 1 to 4 of the European Parliament Decision 3052/95/EC number. Dietary supplements are not trying to replace a balanced and varied diet, are presented only in order to supplement the intake of nutrients of a normal diet. Neither treat, prevent, diagnose or cure any disease, acts attributable to drugs, as defined by European Directive 2004/27/EC of 31 March, the Council and European Parliament on medicinal products.